A Retrospective Analysis of Antithrombin III Replacement Therapy for the Treatment of Hepatic Sinusoidal Obstruction Syndrome in Children Following Hematopoietic Stem Cell Transplantation

Miriam Kim; Seema Rao; Jens C. Eickhoff; Kenneth B. Desantes; Christian M. Capitini

doi:10.1097/MPH.0000000000001422

A Retrospective Analysis of Antithrombin III Replacement Therapy for the Treatment of Hepatic Sinusoidal Obstruction Syndrome in Children Following Hematopoietic Stem Cell Transplantation

Miriam Kim, Seema Rao, Jens C. Eickhoff, Kenneth B. Desantes, Christian M. Capitini

Pediatric Blood & Marrow Transplant & Cellular Therapy

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Hepatic sinusoidal obstruction syndrome (SOS) remains a serious complication of hematopoietic stem cell transplantation (HSCT). In this single institution retrospective case series, 18 children developed SOS after HSCT. Patients were treated with antithrombin III (ATIII), defibrotide, or ATIII followed by defibrotide. Twelve of 13 patients who were treated with ATIII therapy alone had complete resolution of SOS, including 4 of 5 children with severe SOS. In this limited cohort, ATIII was safe and successfully prevented progression of hepatic SOS following HSCT in the majority of children at our center.

Original language	English (US)
Pages (from-to)	145-148
Number of pages	4
Journal	Journal of pediatric hematology/oncology
Volume	42
Issue number	2
DOIs	https://doi.org/10.1097/MPH.0000000000001422
State	Published - Mar 1 2020

Bibliographical note

Funding Information:
M.K. is supported by a St. Baldrick’s Foundation Fellowship award. S.R. was supported by an National Institutes of Health (NIH) grant T32 CA009614. C.M.C. is supported by the NIH/National Cancer Insti-tute grant K08 CA174750. None of these funding sources had any input in the study design, analysis, manuscript preparation, or deci-sion to submit for publication.

Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

BMT
antithrombin III
sinusoidal obstruction syndrome
stem cell transplantation
venoocclusive disease

Publisher link

10.1097/MPH.0000000000001422

Find It

Find It at U of M Libraries

Cite this

A Retrospective Analysis of Antithrombin III Replacement Therapy for the Treatment of Hepatic Sinusoidal Obstruction Syndrome in Children Following Hematopoietic Stem Cell Transplantation. / Kim, Miriam; Rao, Seema; Eickhoff, Jens C. et al.
In: Journal of pediatric hematology/oncology, Vol. 42, No. 2, 01.03.2020, p. 145-148.

Research output: Contribution to journal › Article › peer-review

Kim, M, Rao, S, Eickhoff, JC, Desantes, KB & Capitini, CM 2020, 'A Retrospective Analysis of Antithrombin III Replacement Therapy for the Treatment of Hepatic Sinusoidal Obstruction Syndrome in Children Following Hematopoietic Stem Cell Transplantation', Journal of pediatric hematology/oncology, vol. 42, no. 2, pp. 145-148. https://doi.org/10.1097/MPH.0000000000001422

@article{9fce8604c4cf4f3e948ff3790d42ad4f,

title = "A Retrospective Analysis of Antithrombin III Replacement Therapy for the Treatment of Hepatic Sinusoidal Obstruction Syndrome in Children Following Hematopoietic Stem Cell Transplantation",

abstract = "Hepatic sinusoidal obstruction syndrome (SOS) remains a serious complication of hematopoietic stem cell transplantation (HSCT). In this single institution retrospective case series, 18 children developed SOS after HSCT. Patients were treated with antithrombin III (ATIII), defibrotide, or ATIII followed by defibrotide. Twelve of 13 patients who were treated with ATIII therapy alone had complete resolution of SOS, including 4 of 5 children with severe SOS. In this limited cohort, ATIII was safe and successfully prevented progression of hepatic SOS following HSCT in the majority of children at our center.",

keywords = "BMT, antithrombin III, sinusoidal obstruction syndrome, stem cell transplantation, venoocclusive disease",

author = "Miriam Kim and Seema Rao and Eickhoff, {Jens C.} and Desantes, {Kenneth B.} and Capitini, {Christian M.}",

note = "Funding Information: M.K. is supported by a St. Baldrick{\textquoteright}s Foundation Fellowship award. S.R. was supported by an National Institutes of Health (NIH) grant T32 CA009614. C.M.C. is supported by the NIH/National Cancer Insti-tute grant K08 CA174750. None of these funding sources had any input in the study design, analysis, manuscript preparation, or deci-sion to submit for publication. Publisher Copyright: {\textcopyright} 2019 Wolters Kluwer Health, Inc. All rights reserved.",

year = "2020",

month = mar,

day = "1",

doi = "10.1097/MPH.0000000000001422",

language = "English (US)",

volume = "42",

pages = "145--148",

journal = "Journal of pediatric hematology/oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - A Retrospective Analysis of Antithrombin III Replacement Therapy for the Treatment of Hepatic Sinusoidal Obstruction Syndrome in Children Following Hematopoietic Stem Cell Transplantation

AU - Kim, Miriam

AU - Rao, Seema

AU - Eickhoff, Jens C.

AU - Desantes, Kenneth B.

AU - Capitini, Christian M.

N1 - Funding Information: M.K. is supported by a St. Baldrick’s Foundation Fellowship award. S.R. was supported by an National Institutes of Health (NIH) grant T32 CA009614. C.M.C. is supported by the NIH/National Cancer Insti-tute grant K08 CA174750. None of these funding sources had any input in the study design, analysis, manuscript preparation, or deci-sion to submit for publication. Publisher Copyright: © 2019 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Hepatic sinusoidal obstruction syndrome (SOS) remains a serious complication of hematopoietic stem cell transplantation (HSCT). In this single institution retrospective case series, 18 children developed SOS after HSCT. Patients were treated with antithrombin III (ATIII), defibrotide, or ATIII followed by defibrotide. Twelve of 13 patients who were treated with ATIII therapy alone had complete resolution of SOS, including 4 of 5 children with severe SOS. In this limited cohort, ATIII was safe and successfully prevented progression of hepatic SOS following HSCT in the majority of children at our center.

AB - Hepatic sinusoidal obstruction syndrome (SOS) remains a serious complication of hematopoietic stem cell transplantation (HSCT). In this single institution retrospective case series, 18 children developed SOS after HSCT. Patients were treated with antithrombin III (ATIII), defibrotide, or ATIII followed by defibrotide. Twelve of 13 patients who were treated with ATIII therapy alone had complete resolution of SOS, including 4 of 5 children with severe SOS. In this limited cohort, ATIII was safe and successfully prevented progression of hepatic SOS following HSCT in the majority of children at our center.

KW - BMT

KW - antithrombin III

KW - sinusoidal obstruction syndrome

KW - stem cell transplantation

KW - venoocclusive disease

UR - http://www.scopus.com/inward/record.url?scp=85060376328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060376328&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001422

DO - 10.1097/MPH.0000000000001422

M3 - Article

C2 - 30676436

AN - SCOPUS:85060376328

SN - 1077-4114

VL - 42

SP - 145

EP - 148

JO - Journal of pediatric hematology/oncology

JF - Journal of pediatric hematology/oncology

IS - 2

ER -

A Retrospective Analysis of Antithrombin III Replacement Therapy for the Treatment of Hepatic Sinusoidal Obstruction Syndrome in Children Following Hematopoietic Stem Cell Transplantation

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this